Coroners Removal Service within the Boroughs of Sefton, Knowsley and St Helens For The Period 1st December 2026 to 30th November 2029 with the Option for 2 x 12 Month Extensions

NHS Essex Integrated Care Board is undertaking a Competitive Process under the Health Care Services (Provider Selection Regime) Regulations 2023 for the award of a General Medical Services (GMS) contract for Tollgate Practice, Stanway, Colchester. The Authority seeks a suitably qualified provider to deliver primary medical services to a registered patient population of approximately 10,206 patients. Services will be provided under a nationally prescribed GMS contract from the existing practice premises and will include the delivery of core primary medical services, management of the registered patient list, clinical governance, safeguarding, information governance and integration with local health and care services. This procurement is being undertaken to secure the long-term provision of stable, resilient and high-quality primary medical services for the local population. Due to the fixed practice location, established patient list and requirement for uninterrupted service delivery, bidders must demonstrate the ability to mobilise and maintain an appropriately qualified workforce and robust governance arrangements from contract commencement. The contract will be awarded following evaluation against the key criteria set out in the Health Care Services (Provider Selection Regime) Regulations 2023. The estimated contract value is £21,896,491.60, calculated using a notional 20-year term for valuation purposes only. The contract itself is a perpetual GMS contract and is not time limited. Additional information: To express interest and participate in the tender, please register and apply via Atamis e-sourcing portal https://health-family.force.com/s/Welcome. Should Tenderers have any queries, or having problems using the portal, they should contact Helpdesk at: Phone: 0800 9956035 E-mail: support-health@atamis.co.uk

Nova Education Trust is a forward-thinking multi-academy trust committed to delivering exceptional educational outcomes across its family of Trusts. With a strong presence in the East Midlands, the Trust is driven by a shared vision to create transformational teaching and learning experiences that empower every young learner to thrive. Nova Education Trust is seeking to establish a compliant, scalable and outcome-focused Inclusion Centre service across its family of schools. The Trust is seeking a suitably qualified and experienced provider to deliver, manage and continuously develop Inclusion Centre services across one or more schools within the Trust. The service will provide targeted intervention, behaviour support, pastoral support and reintegration programmes for pupils who are at risk of suspension, permanent exclusion, disengagement from education, poor attendance or other barriers to learning. To access this competition: Registered: Login to https://suppliers.multiquote.com and view the opportunity CA18386. Not registered: Visit https://suppliers.multiquote.com then register and quote CA18386 as the reason for registration. Any queries please contact MultiQuote on 020 3920 8054.

Lincolnshire Community Health Services NHS Trust (LCHS) is seeking provider(s) to deliver Community Pharmacy Services through a PSR Competitive Process. The procurement comprises Lot 1: Medicines Supply, Dispensing and Distribution Services and Lot 2: Clinical Pharmacy Support Services. Contract term: 3 years plus up to 2 x 12-month extensions. Providers may bid for one or both Lots. Service commencement date: 01 April 2027. Additional information: To express interest and participate in the tender, please register and apply via Atamis e-sourcing portal https://health-family.force.com/s/Welcome. Should Tenderers have any queries, or having problems using the portal, they should contact Helpdesk at: Phone: 0800 9956035 E-mail: support-health@atamis.co.uk Provider Selection Regime (PSR) Competitive Process Lincolnshire Community Health Services NHS Trust (LCHS) is inviting suitably qualified, experienced and competent providers to participate in a Provider Selection Regime (PSR) Competitive Process for the provision of Community Pharmacy Services across Lincolnshire. The procurement is being undertaken in accordance with the Health Care Services (Provider Selection Regime) Regulations 2023 and has been structured to secure high-quality, resilient and sustainable pharmaceutical services that support patient care, medicines optimisation, medicines safety and service delivery across a diverse community healthcare environment. The procurement is divided into two Lots, allowing providers to bid for one Lot, both Lots, or any combination permitted within the procurement documentation: Lot 1 - Medicines Supply, Dispensing and Distribution Services The successful provider will be responsible for the procurement, dispensing, storage, distribution and supply of medicines and associated pharmaceutical products across a wide range of services. The service supports Community Hospitals, Urgent Treatment Centres (UTCs), Community Nursing Services, Integrated Community Teams, Home Visiting Services, Vaccination Services, Sexual Health Services and specialist HIV Services delivered across Lincolnshire and neighbouring areas. The provider will be expected to maintain robust medicines governance arrangements, support urgent and out-of-hours medicines requirements, manage medicines shortages and recalls, and provide a resilient medicines supply chain capable of supporting a geographically dispersed healthcare organisation. Lot 2 - Clinical Pharmacy Support Services The successful provider will deliver a comprehensive clinical pharmacy service supporting Community Hospitals, Urgent Treatment Centres, Butterfly Hospice, Sexual Health Services and HIV Services. Services will include medicines reconciliation, medicines optimisation, clinical pharmacy review, multidisciplinary team support, prescribing support, medicines governance, audit, education and training, patient counselling, specialist HIV pharmacy support and participation in quality improvement initiatives. Providers will be expected to deploy an appropriately skilled workforce comprising pharmacists, independent prescribers and pharmacy technicians capable of delivering consistent and high-quality pharmaceutical care across multiple sites.

Kent County Council, on behalf of the Kent and Medway Suicide Prevention Programme and in partnership with the Kent and Medway Integrated Care Board, is seeking market engagement to inform the future procurement of a Specialist Bereavement Support Service for people affected by suicide across Kent and Medway. The service will provide timely, accessible and trauma-informed emotional and practical support to individuals impacted by suicide, including family members, friends, colleagues, witnesses and professionals. The future provider will be expected to deliver a flexible countywide service through a combination of face-to-face, telephone and virtual support, working closely with health, community and voluntary sector partners. The contract is anticipated to commence on 1 April 2027 for an initial period of three years, with the option to extend for up to two further years. Kent County Council welcomes engagement from organisations interested in helping to shape the future service and deliver innovative, high-quality support for residents affected by suicide bereavement.

The Life Sciences Transformational R&D Investment Fund Pilot offers capital grants to support large-scale R&D projects in the UK life sciences sector (eligible projects must exceed £100 million in total costs). It aims to boost research and development within the UK's Life Sciences sector by supporting large-scale investments focused on innovation and strengthening health resilience, as well as projects with the potential to generate economic benefits. This fund complements the separate Life Sciences Innovative Manufacturing Fund (LSIMF).

UK registered businesses can apply for funding for life science manufacturing capital investment projects which help increase UK health resilience.

Expected Outcome: This action will establish a strategic European initiative to develop scalable, modular, and interoperable photonic quantum computing platforms. Proposals for this topic are expected to address and provide credible solutions to at least two major technical roadblocks currently limiting the advancement of photonic quantum computing such as: The lack of deterministic, high-efficiency photonic entanglement and loss-tolerant architectures suitable for fault-tolerant scaling The absence of a standardised, integrated control stack combining photonic hardware, firmware, and system software with reliable benchmarking across platforms Project results are expected to contribute to the following expected outcomes: By 2028, demonstration of a photonic NISQ processor with ≥100 photonic qubits, integrating deterministic single-photon sources, low-loss waveguides, on-chip detectors, and a firmware stack (scheduler, controller, compiler), validated via hardware-agnostic benchmarks and hybrid photonic-HPC applications demonstrating classical-quantum crossover By 2030, delivery of a full-stack, high-connectivity photonic quantum computer, with modular scalability, integrated…

Expected Impact: The action under this topic is expected to achieve the following impacts: Accelerate EU access to more cost-effective interventions in an increasingly ageing population by identifying personalised treatment approaches for elderly-onset immune diseases. Decrease disease risk later in life by defining specific prevention strategies based on ageing biomarkers and risk factors. Halt age-associated disease exacerbation by the identification of predictive and digital biomarkers that can stratify patients for early intervention. Improve quality of life for healthy individuals and patients by preventing further health decline, avoiding escalating care costs, and properly stratifying individuals earlier in the diagnostic pathway. Accelerate adoption of innovative diagnostic, preventative, and therapeutic strategies, strengthening the EU’s position as a healthcare innovator. Evaluate digital biomarker as potential regulatory endpoints in the ultimate goal to develop medicines for ‘healthy ageing’. Integrate fragmented research efforts by bringing together health industry sectors and stakeholders to develop clinical and multi-omics data integration capabilities. Enable new…

Expected Impact: The action under this topic is expected to achieve the following impacts: Faster and more informed decision-making through the use of an AI-driven NAM (AI Foundation Toxicology Model) and increased efficiency through rapid processing of vast amounts of data [1] . Increased consistency and standardisation in a NAM-based approach, specifically an AI model, used by industry in the efficient development, testing and production of safe and effective innovative health technologies, improving industrial competitiveness. Regulatory adoption of a NAM-enabled second species waiver model (AI Foundation Toxicology Model) and weight-of-evidence framework, in line with recommendations and more consistent global decision-making on waiving second species testing. Reduction in animal use, accelerated timelines and lower costs, enhancing the competitiveness of the European health industry through economical and ethical benefits. Improved public health as patients will benefit from safe and effective medicines developed faster using validated NAMs. The action is expected to contribute to the EU Directive (2010/63/EU) [2] on the protection of animals used for scientific purposes and…

Expected Outcome: This flagship pilot is the culmination of the entire activity catalogue carried out by the CCAM Partnership since its launch in 2021. It will combine in one project the most promising CCAM use-cases across three key domains, with the technological advancements from all its R&I clusters [1] supporting and enabling CCAM systems and services towards market uptake. This action is expected to contribute to all the following outcomes: Large-scale demonstrations of inclusive, user-oriented, and well-integrated CCAM systems and services for people and goods in mixed traffic through Field Operational Tests (FOTs), Technology Pilots, and Living Labs, building upon advanced and emerging SAE Level 2 systems to move towards SAE Level 3 and 4 functionalities, at multiple test sites and corridors showcasing CCAM potential [2] , for a minimum of 12 months. Validation of enabling technologies that facilitate the extension of Operational Design Domains (ODDs) in large-scale operations and enhance perception performance under poor lighting and adverse weather conditions in large-scale demonstrations and pilots. Assessment of deployment readiness and demonstration of technological…